Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of gene marker in prognosis of lung cancer

A prognostic judgment and marker technology, applied in the field of medical diagnosis, can solve the problems of expensive TMB detection and difficulty in establishing consensus, and achieve the effect of avoiding statistical analysis, strong accuracy, and high evaluation accuracy.

Pending Publication Date: 2020-07-24
SHANGHAI ORIGIMED CO LTD
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It’s just that TMB testing is expensive, and it’s difficult to establish a consensus on TMB calculations in different companies or laboratories, and age is also a big influencing factor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of gene marker in prognosis of lung cancer
  • Application of gene marker in prognosis of lung cancer
  • Application of gene marker in prognosis of lung cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0074] In this example, we collected 37 FFPE tumor samples from Chinese patients with non-small cell lung cancer (NSCLC).

[0075] These samples are mainly concentrated in clinical stage III and IV samples. The overall survival period of the disease, death and other clinical information such as gender, age, pathological type, PD-L1 and other information were collected.

[0076] Use the kit for lung cancer prognosis prediction of the present invention to extract the RNA in the corresponding lung cancer FFPE tumor samples of these 37 lung cancer patients, perform transcriptome sequencing on the RNA corresponding to these samples, and then process the sequencing results to obtain lung cancer prognosis prediction The evaluation gene group.

[0077] The specific process of using the above kit to extract RNA is as follows:

[0078] 1. Use a clean scalpel to scrape the FFPE sample into a 1.5ml centrifuge tube, close the cap and microcentrifuge to collect all wax debris to the botto...

Embodiment 2

[0115] Validation determines whether the pending evaluation gene group is an evaluation gene group.

[0116] In order to do prognostic verification analysis, select the lung cancer training sample as in Example 1. Here, similarly, according to the same predetermined definition method as in Example 1, 37 clinical training samples of lung cancer are determined as good prognosis samples (best_response=1) or Bad prognosis samples (best_response=0).

[0117] Then, in the same way, do cox survival analysis on all samples with good prognosis to get a result A, and do cox survival analysis on all samples with poor prognosis to get a result and analyze the significance of survival difference between results A and B, when When the obtained result is significant, it is determined that the undetermined evaluation gene group obtained in Example 1 is an evaluation gene group that can be used for evaluating the prognosis of lung cancer. The result is as Figure 9 .

[0118] Fig...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of a detection agent used for detecting the expression quantities of the following genes in preparation of a kit used for recurrence risk assessment, prognosis, treatment or adjuvant therapy of lung cancer: CD1A, CD1B, CD1C, CD1D, MR1, AQP3 and CEACAM3. According to change of the expression quantities of the genes, the marker is used for accurately evaluating prognosis of a patient with lung cancer; and complex and fussy statistical analysis is avoided. A gene group detection result in the invention can provide accurate therapeutic effect evaluation for clinical doctors and patients; simultaneously, a patient, who is not sensitive to a conventional treatment scheme also can be detected; a doctor is helped to select a new effective clinical treatment scheme; and thus, individualized treatment is really realized.

Description

technical field [0001] The invention relates to the field of medical diagnosis, in particular to the application of a gene marker in the prognosis judgment of lung cancer. Background technique [0002] Lung cancer is one of the malignant tumors with the fastest increasing morbidity and mortality and the greatest threat to the health and life of the population. Globally, the morbidity and mortality of lung cancer are extremely high and are on the rise. According to global statistics in 2019, the incidence and mortality of lung cancer in males rank first among malignant tumors, while the incidence and mortality in females rank second. A large amount of data shows that long-term heavy smoking is closely related to the occurrence of lung cancer. In addition, such as environmental pollution, passive smoking and occupational hazards are also important factors causing lung cancer. [0003] Clinically, lung cancer is divided into two types: small cell lung cancer (SCLC) and non-s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886G01N33/574
CPCC12Q1/6886G01N33/57423G01N33/57484C12Q2600/118C12Q2600/158C12Q2600/106G01N2333/70503G01N2333/70539C07K14/70596
Inventor 施巍炜柳文进黄璐嘉
Owner SHANGHAI ORIGIMED CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com